Operating
Equity Securities, FV-NI, Gain (Loss)
DexCom Equity Securities, FV-NI, Gain (Loss) decreased by 100.0% to $0 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from -$4.2M to $0.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ4 2023
Last reportedQ1 2026Apr 30, 2026
Metric ID:
operating_equity_securities_fv_ni_gain_lossHistorical Data
5 periods
| Q4 '23 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $900K | $400K | -$4.2M | $82.7M | $0 |
| QoQ Change | — | -55.6% | <-999% | >999% | -100.0% |
| YoY Change | — | — | — | >999% | +100.0% |
Range-$4.2M – $82.7M
CAGR-100.0%
Avg YoY Growth>999%
Median YoY Growth>999%
Equity Securities, FV-NI, Gain (Loss) at Other Companies
Frequently Asked Questions
- What is DexCom's equity securities, fv-ni, gain (loss)?
- DexCom (DXCM) reported equity securities, fv-ni, gain (loss) of $0 in Q1 2026.
- How has DexCom's equity securities, fv-ni, gain (loss) changed year-over-year?
- DexCom's equity securities, fv-ni, gain (loss) increased by 100.0% year-over-year, from -$4.2M to $0.